Intellipharmaceutics International Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products, with a particular emphasis in the controlled-release and opioid abuse deterrence space. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed several drug delivery systems and a pipeline of products and product candidates in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. It also provides analytical services.